SGLT2 inhibitors have been shown to reduce endothelial dysfunction through a variety of mechanisms, which may be particularly advantageous in those treated with VSPIs or other classes known to disrupt endothelial homeostasis [184]. Here, SLC5A2 is linked to endothelial dysfunction.